SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pharmadrug Inc. (LMLLF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 6/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LMLLF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.01
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.61 |
$0.00 |
$-396K |
- |
| 2016 |
$-12.53 |
$0.00 |
$-7.51M |
- |
| 2017 |
$-0.21 |
$0.00 |
$-115K |
- |
| 2018 |
$-1.98 |
$0.00 |
$-3.89M |
- |
| 2019 |
$-0.63 |
$610.58K |
$-6.29M |
-1030.2% |
| 2020 |
$-0.26 |
$683.67K |
$-5.15M |
-753.3% |
| 2021 |
$-0.12 |
$7.01K |
$-5.87M |
-83806.5% |
| 2022 |
$-0.18 |
$0.00 |
$-8.88M |
- |
| 2023 |
$-0.23 |
$0.00 |
$-13.2M |
- |
| 2024 |
$-0.01 |
$0.00 |
$-793K |
- |
